Applied genetics

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer

Retrieved on: 
Thursday, May 6, 2021
Oncology, Health, Diabetes, Research, Pharmaceutical, Science, Branches of biology, Biology, Life sciences, Lung cancer, Applied genetics, Biotechnology, Medical genetics, Emerging technologies, Non-small-cell lung carcinoma, Cancer, Gene therapy

\xe2\x80\x9cThese new technologies further add to our arsenal of combination therapies for REQORSA, and may enable us to improve patient outcomes through the advancement of multiple therapeutic approaches.\xe2\x80\x9d\nGenprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Key Points: 
  • \xe2\x80\x9cThese new technologies further add to our arsenal of combination therapies for REQORSA, and may enable us to improve patient outcomes through the advancement of multiple therapeutic approaches.\xe2\x80\x9d\nGenprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
  • Genprex\xe2\x80\x99s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
  • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
  • The Company\xe2\x80\x99s lead product candidate, REQORSA\xe2\x84\xa2 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, May 6, 2021
Biotechnology, Pharmaceutical, General Health, Health, FDA, Genetics, Clinical trials, Other Health, Branches of biology, Life sciences, Health sciences, Applied genetics, XC2, Therapy, Gene therapy, Vesting, Intel X99

The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).\nThe stock options were granted as inducements material to the new employees\xe2\x80\x99 acceptance of employment with the company and were approved by the Compensation Committee of the company\xe2\x80\x99s Board of Directors.

Key Points: 
  • The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).\nThe stock options were granted as inducements material to the new employees\xe2\x80\x99 acceptance of employment with the company and were approved by the Compensation Committee of the company\xe2\x80\x99s Board of Directors.
  • Vesting of the option awards is subject to continued service with AVROBIO by the employee through the applicable vesting dates.\nOur vision is to bring personalized gene therapy to the world.
  • AVROBIO is powered by our industry leading plato\xc2\xae gene therapy platform, our foundation designed to deliver gene therapy worldwide.
  • AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210506005093/en/\n'

Excision BioTherapeutics Adds Gene Therapy Expert Nicole Paulk, Ph.D., to its Scientific Advisory Board

Retrieved on: 
Wednesday, May 5, 2021
Branches of biology, Life sciences, Biology, Genetic engineering, Applied genetics, Medical genetics, Biotechnology, Bioethics, Gene therapy, Therapy, AAV, Antiviral drug

b'SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (\xe2\x80\x9cExcision\xe2\x80\x9d), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of gene therapy and rare disease expert, Nicole Paulk, Ph.D., to its Scientific Advisory Board (SAB).\n\xe2\x80\x9cWe would like to give a warm welcome to gene therapy pioneer Dr. Nicole Paulk as our newest SAB member.

Key Points: 
  • b'SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (\xe2\x80\x9cExcision\xe2\x80\x9d), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of gene therapy and rare disease expert, Nicole Paulk, Ph.D., to its Scientific Advisory Board (SAB).\n\xe2\x80\x9cWe would like to give a warm welcome to gene therapy pioneer Dr. Nicole Paulk as our newest SAB member.
  • \xe2\x80\x9cAs one of the world\xe2\x80\x99s preeminent experts in viral gene therapy, Nicole has already made substantial contributions to Excision\xe2\x80\x99s programs targeting HIV, Hepatitis B and Herpes Virus.\xe2\x80\x9d\nDr.
  • Paulk is an Assistant Professor of AAV Gene Therapy at the University of California San Francisco (UCSF) Dept.
  • of Pediatrics, where she developed enabling technologies in host-virus interactions, AAV gene therapy, and preclinical therapeutic development.

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, May 4, 2021
Oncology, FDA, Health, Diabetes, Clinical trials, Pharmaceutical, Branches of biology, Life sciences, Health sciences, Lung cancer, Applied genetics, Non-small-cell lung carcinoma, Therapy, Gene therapy, Cancer

The final protocol is subject to change based on input from investigators.\nGenprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Key Points: 
  • The final protocol is subject to change based on input from investigators.\nGenprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
  • Genprex\xe2\x80\x99s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
  • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
  • The Company\xe2\x80\x99s lead product candidate, REQORSA\xe2\x84\xa2 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

Shape Therapeutics Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Tuesday, May 4, 2021
Branches of biology, Life sciences, Biology, Biotechnology, Emerging technologies, Applied genetics, Gene delivery, Medical genetics, Gene therapy, Therapy

ShapeTX gene therapy platform comprises RNAskipTM, RNAfixTM, RNAswitch payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines.

Key Points: 
  • ShapeTX gene therapy platform comprises RNAskipTM, RNAfixTM, RNAswitch payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines.
  • At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies.
  • ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients.
  • Shape Life!\n"

Affinia Therapeutics Closes $110 Million Series B Financing

Retrieved on: 
Monday, May 3, 2021
Branches of biology, Biology, Applied genetics, Genetics, Medical genetics, Genetic engineering, Biotechnology, Gene delivery, Adeno-associated virus, Affinia, Gene therapy

b'WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced it has closed an oversubscribed $110 million Series B financing with a premier syndicate of life science investors, co-led by EcoR1 Capital and Farallon Capital Management.

Key Points: 
  • b'WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced it has closed an oversubscribed $110 million Series B financing with a premier syndicate of life science investors, co-led by EcoR1 Capital and Farallon Capital Management.
  • Existing investors Atlas Venture, F-Prime Capital, Lonza, Mass General Brigham Ventures, and New Enterprise Associates (NEA) also participated in the round.
  • \xe2\x80\x9cWe are excited to partner with this syndicate of top investors to expand our platform to regulatory elements and work toward the next generation of one-time, potentially curative medicines for broader use.\xe2\x80\x9d\nIn 2020, Affinia Therapeutics announced a Series A financing and a multi-year research collaboration with Vertex Pharmaceuticals.
  • In connection with the Series B financing, Caroline Stout, partner at EcoR1 Capital, has been appointed to Affinia Therapeutics\xe2\x80\x99 board of directors.\n\xe2\x80\x9cGene therapies with novel vectors and regulatory elements have the potential to benefit a broad range of both rare and non-rare diseases,\xe2\x80\x9d said Ms. Stout.

4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference

Retrieved on: 
Friday, April 30, 2021
Branches of biology, Life sciences, Biology, Molecular biology, Biotechnology, Emerging technologies, Applied genetics, Bioethics, Therapy, Gene therapy

b'EMERYVILLE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will present at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13 at 2:00 p.m. PT.\nA live audio webcast of the presentation will be available by visiting the \xe2\x80\x9cInvestors & Media\xe2\x80\x9d section of the 4DMT website at www.4dmoleculartherapeutics.com.

Key Points: 
  • b'EMERYVILLE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will present at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13 at 2:00 p.m. PT.\nA live audio webcast of the presentation will be available by visiting the \xe2\x80\x9cInvestors & Media\xe2\x80\x9d section of the 4DMT website at www.4dmoleculartherapeutics.com.
  • A replay of the webcast will be available for at least two weeks following the live event.\n4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies.
  • 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products.
  • The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology.

Personalis to Present at the 2021 Bank of America Healthcare Conference

Retrieved on: 
Thursday, April 29, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Biotechnology, Applied genetics, Biology, Oncogenomics, Life sciences

b'Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time.\nPersonalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality.

Key Points: 
  • b'Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 5:00 p.m. Eastern Time.\nPersonalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality.
  • Personalis operates one of the largest sequencing programs globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veterans Program.
  • In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient\xe2\x80\x99s cancer and immune response.
  • The Personalis\xc2\xae Clinical Laboratory is GxP aligned as well as CLIA\xe2\x80\x9988-certified and CAP-accredited.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005154/en/\n'

Forge Biologics Announces Closing of $120 Million Series B Financing

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Life sciences, Biology, Branches of biology, Biotechnology, Pharmaceutical industry, Applied genetics, Gene delivery, Biopharmaceutical, Pharmacy, Gene therapy

b'Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing.

Key Points: 
  • b'Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing.
  • The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace.
  • \xe2\x80\x9cWe have built Forge into a focused gene therapy development engine with a firm commitment to helping our clients provide potentially life-saving gene therapies to patients.
  • By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005365/en/\n'

Sio Gene Therapies Announces Four Upcoming Oral Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Biology, Articles, Emerging technologies, Gene delivery, Medical genetics, Molecular biology, Applied genetics, Gene therapy, Forward-looking statement, Sio

The gene therapy is delivered intravenously, which has the potential to broadly transduce the central nervous system and treat peripheral manifestations of the disease as well.

Key Points: 
  • The gene therapy is delivered intravenously, which has the potential to broadly transduce the central nervous system and treat peripheral manifestations of the disease as well.
  • We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson\xe2\x80\x99s disease, which affects millions of patients globally.
  • All forward-looking statements are based on estimates and assumptions by Sio\xe2\x80\x99s management that, although Sio believes to be reasonable, are inherently uncertain.
  • All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Sio expected.